| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| L.I.A. Pure Capital Ltd | 10% | -0.2% | $2,093,139 | +$935,587 | 5,980,397 | +81% | L.I.A. Pure Capital Ltd. | 03 Dec 2025 |
| Capitalink Ltd. | 10% | -0.2% | $2,093,139 | +$935,587 | 5,980,397 | +81% | Capitalink Ltd. | 03 Dec 2025 |
| Daniel Nissim | 10% | $3,009,635 | 3,307,291 | Nissim Daniel | 19 Nov 2025 | |||
| Iroquois Capital Management, LLC | 9.9% | +62% | $549,158 | +$138,124 | 603,470 | +34% | Richard Abbe | 30 Sep 2025 |
| AdvisorShares Trust | 4.8% | $177,102 | 205,933 | AdvisorShares Trust | 30 Jun 2025 |
As of 30 Sep 2025, 7 institutional investors reported holding 281,131 shares of Clearmind Medicine Inc. - Common Shares, no par value per share (CMND). This represents 0.47% of the company’s total 59,983,922 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 281,131 | $288,305 | +$41,508 | $1.02 | 7 |
| 2025 Q2 | 244,330 | $216,133 | -$13,983 | $0.88 | 7 |
| 2025 Q1 | 601,206 | $5,451,442 | -$30,388 | $1.04 | 6 |
| 2024 Q4 | 612,804 | $5,491,207 | -$46,684 | $1.38 | 9 |
| 2024 Q3 | 702,419 | $5,494,319 | +$5,284,113 | $1.22 | 8 |
| 2024 Q2 | 165,796 | $276,008 | +$33,327 | $1.68 | 4 |
| 2024 Q1 | 153,477 | $175,314 | +$69,644 | $1.14 | 4 |
| 2023 Q4 | 92,693 | $260,467 | +$260,467 | $2.81 | 1 |